ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PMN ProMIS Neurosciences Inc

Closed 12-22 16:00:00 EST

8.13

-0.42

-4.91%

盘后8.10

-0.03-0.35%

19:20 EST

High8.84	Low8.05	Vol27.63K
Open8.65	D1 Closing8.55	Amplitude9.24%
Mkt Cap17.50M	Tradable Cap8.29M	Total Shares2.15M
T/O235.11K	T/O Rate2.71%	Tradable Shares1.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PMN","market":"US","secType":"STK","nameCN":"ProMIS Neurosciences Inc","latestPrice":8.13,"timestamp":1766437200000,"preClose":8.55,"halted":0,"volume":27630,"hourTrading":{"tag":"盘后","latestPrice":8.1012,"preClose":8.13,"latestTime":"19:20 EST","volume":266,"amount":2175.9936,"timestamp":1766449212048},"delay":0,"floatShares":1019940,"shares":2152444,"eps":-20.049492,"marketStatus":"Closed","change":-0.42,"latestTime":"12-22 16:00:00 EST","open":8.65,"high":8.84,"low":8.05,"amount":235110.30120000002,"amplitude":0.092398,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-20.049492,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766480400000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":8.55,"preHourTrading":{"tag":"盘前","latestPrice":8.538,"preClose":8.6,"latestTime":"08:54 EST","volume":824,"amount":7207.801568,"timestamp":1766411692897},"postHourTrading":{"tag":"盘后","latestPrice":8.1012,"preClose":8.13,"latestTime":"19:20 EST","volume":266,"amount":2175.9936,"timestamp":1766449212048},"volumeRatio":1.159015},"requestUrl":"/m/hq/s/PMN/tweets","defaultTab":"tweets","newsList":[{"id":"2592055849","title":"BRIEF-Promis Neurosciences Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592055849","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592055849?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:39","pubTimestamp":1766061565,"startTime":"0","endTime":"0","summary":"BRIEF-Promis Neurosciences Exceeds Target Enrollment In Precise-Ad Phase 1B Cli Trial Dec 18 (Reuters) - ProMIS Neurosciences Inc PMN.O:PROMIS NEUROSCIENCES EXCEEDS TARGET ENROLLMENT IN PRECISE-AD PHA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA17JLKX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"gpt_icon":0},{"id":"2592903776","title":"ProMIS Neurosciences Completes Enrollment for Phase 1b Trial of PMN310 in Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2592903776","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592903776?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:30","pubTimestamp":1766061024,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc. has announced the completion of patient enrollment for its PRECISE-AD Phase 1b clinical trial of PMN310, a therapeutic antibody candidate for the treatment of Alzheimer's disease. The trial enrolled 144 patients with mild cognitive impairment or early Alzheimer's disease, exceeding the initial target. The study is a randomized, double-blind, placebo-controlled trial designed to assess the safety, tolerability, pharmacokinetics, biomarkers, and clinical effects of PMN310, which targets toxic soluble amyloid-beta oligomers. Interim blinded data from a 6-month analysis are expected in the second quarter of 2026, with final unblinded top-line results anticipated in the fourth quarter of 2026. No treatment-related serious adverse events have been reported so far. Results have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL49nLWY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014039.USD","PMN","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4588","NDAQ","IE00BKPKM429.USD","BK4585","SG9999014005.SGD","LU2210149790.SGD","BK4112","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2592903063","title":"ProMIS Neurosciences Inc - Interim Analysis Expected in Q2 2026, Final Results in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592903063","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592903063?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:30","pubTimestamp":1766061000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA17JLKX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMN"],"gpt_icon":0},{"id":"2592790326","title":"ProMIS Neurosciences Exceeds Target Enrollment in Precise-Ad Phase 1B Clinical Trial of Pmn310 in Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2592790326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592790326?lang=en_us&edition=fundamental","pubTime":"2025-12-18 20:30","pubTimestamp":1766061000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA17JLKX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMN","BK4139"],"gpt_icon":0},{"id":"2590584231","title":"ProMIS Neurosciences Advances PMN310 Alzheimer’s Trial With Interim Results Expected in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2590584231","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590584231?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:30","pubTimestamp":1765369831,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc. has announced progress in its ongoing PRECISE-AD clinical trial evaluating PMN310, an antibody therapeutic targeting toxic Aβ oligomers in Alzheimer's disease. The company is on track to complete enrollment in the study by the end of 2025, with a 6-month interim readout planned for the second quarter of 2026 and top-line results expected in the fourth quarter of 2026. A recent peer-reviewed publication in Alzheimer's & Dementia: Translational Research & Clinical Interventions highlighted experimental and clinical evidence supporting the selective targeting of toxic Aβ oligomers by PMN310, which may improve efficacy and reduce the risk of amyloid-related imaging abnormalities  compared to current Aβ-directed antibodies. The clinical results have not yet been presented and are expected in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL6Bj2Xt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014013.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014021.USD","BK4139","IE00BKPKM429.USD","LU0314104364.USD","BK4112","LU2210149790.SGD","PMN","BK4588","LU2210150020.SGD","NDAQ","IE00B64PRP62.GBP","BK4585","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2588777191","title":"ProMIS Neurosciences Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588777191","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588777191?lang=en_us&edition=fundamental","pubTime":"2025-12-02 00:09","pubTimestamp":1764605340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PMN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 01, 2025 11:09 ET (16:09 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"gpt_icon":0},{"id":"2588727346","title":"BRIEF-Plasma pTau Identified as Key Early Endpoint in Alzheimer's Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727346","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588727346?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:36","pubTimestamp":1764592582,"startTime":"0","endTime":"0","summary":"BRIEF-Plasma pTau Identified as Key Early Endpoint in Alzheimer's ResearchDec 1 (Reuters) - ProMIS Neurosciences Inc PMN.O:PROMIS NEUROSCIENCES ANNOUNCES NEW PEER-REVIEWED PUBLICATION SHOWING PLASMA P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA9ZSHS9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"gpt_icon":0},{"id":"2588000722","title":"ProMIS Neurosciences Announces Interim Phase 1b Trial Readout for PMN310 in Alzheimer's Disease Set for Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2588000722","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588000722?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592220,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc. has announced a new peer-reviewed publication supporting the use of plasma pTau as a predictive early endpoint in Alzheimer's disease clinical trials. The publication validates the company's strategy of employing highly sensitive plasma pTau biomarkers as a core measure in its ongoing Phase 1b PRECISE-AD trial for the investigational therapeutic PMN310. According to ProMIS, blinded 6-month biomarker data, including plasma pTau217, from the PRECISE-AD trial are scheduled for assessment in Q2 2026. The results have not yet been presented; the upcoming interim readout is expected to provide early insights into the potential disease-modifying effects of PMN310.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL8hC28P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4585","IE00BKPKM429.USD","LU2095319765.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","BK4139","IE00B64PRP62.GBP","BK4588","NDAQ","IE00BGHQF748.EUR","LU2210149790.SGD"],"gpt_icon":0},{"id":"2588722004","title":"ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma Ptau as a Predictive Early Endpoint in Alzheimer’s Trials, Supporting Its Ongoing Phase 1B Precise-Ad Trial With Pmn310","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722004","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588722004?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:30","pubTimestamp":1764592201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUA9ZSHS9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PMN","BK4139"],"gpt_icon":0},{"id":"2588724751","title":"ProMIS Neurosciences CEO to Join Fireside Chat at Evercore Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724751","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724751?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:00","pubTimestamp":1764590430,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc. will participate in the 8th Annual Evercore Healthcare Conference on Tuesday, December 2nd, 2025. CEO Neil Warma is scheduled to join a fireside chat and hold investor one-on-one meetings during the event. A live webcast of the presentation will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDLmrPB1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2210150020.SGD","IE00B64PRP62.GBP","LU0314104364.USD","EVR","BK4127","NDAQ","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","BK4585","PMN","BK4112","BK4139","LU2095319765.USD"],"gpt_icon":0},{"id":"2586248538","title":"NASDAQ TRADE HALT CONTINUES  HALT NEWS PENDING AT 03:28 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2586248538","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586248538?lang=en_us&edition=fundamental","pubTime":"2025-11-27 16:28","pubTimestamp":1764232117,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT CONTINUES  HALT NEWS PENDING AT 03:28 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nAQN2LB8OB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"gpt_icon":0},{"id":"2586294514","title":"Promis Neurosciences Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2586294514","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586294514?lang=en_us&edition=fundamental","pubTime":"2025-11-27 08:50","pubTimestamp":1764204621,"startTime":"0","endTime":"0","summary":"19:50 EST Promis Neurosciences (PMN) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/promis-neurosciences-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PMN","BK4139"],"gpt_icon":0},{"id":"2586582235","title":"Analysts Offer Insights on Healthcare Companies: ProMIS Neurosciences (PMN) and Crispr Therapeutics AG (CRSP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586582235","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586582235?lang=en_us&edition=fundamental","pubTime":"2025-11-26 14:30","pubTimestamp":1764138618,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ProMIS Neurosciences (PMN – Research Report) and Cri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-promis-neurosciences-pmn-and-crispr-therapeutics-ag-crsp-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-promis-neurosciences-pmn-and-crispr-therapeutics-ag-crsp-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","XBI","BK4139","BK4210","LU1861559042.SGD","HCSG","BK4556","CRSP","BK4611","BK4137","BK4581","PMN","BK4588","LU0029874061.USD","AG","XLV","LABU","BK4585","LU1861558580.USD"],"gpt_icon":0},{"id":"2585980554","title":"Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2585980554","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585980554?lang=en_us&edition=fundamental","pubTime":"2025-11-24 22:47","pubTimestamp":1763995637,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/25/11/49030696/nasdaq-surges-350-points-enlivex-therapeutics-shares-spike-higher","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INHD","BK4006","CLSDQ","TQQQ","CLSD","BK4122",".IXIC","USAW.SI","IVP","BK4007","TSYW.SI","BK4185","BK4551","QLD","BK4139","BK4539","BK4209","NQmain","TWNP","QID","NVIW.SI","MNQmain","SQQQ","ENLV","BK4548","PMN","USJW.SI","CVAC","PCOM","PSQ","LENZ"],"gpt_icon":1},{"id":"2585462619","title":"ProMIS Neurosciences Announces 1-for-25 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462619","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462619?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:00","pubTimestamp":1763989215,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc. has announced a one-for-twenty-five reverse stock split of its common shares, effective at 12:01 a.m. Eastern Time on November 28, 2025. The shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market the same day, with a new CUSIP number 74346M505. The move aims to increase the market price of the company's shares and address Nasdaq's minimum bid price requirement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL1fXmgc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4585","IE00BKPKM429.USD","LU2095319765.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","BK4139","IE00B64PRP62.GBP","BK4588","NDAQ","IE00BGHQF748.EUR","LU2210149790.SGD"],"gpt_icon":0},{"id":"2585462389","title":"ProMIS Neurosciences Announces Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462389","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462389?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:00","pubTimestamp":1763989202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUAB64MP6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PMN"],"gpt_icon":0},{"id":"2585211734","title":"ProMIS Neurosciences Price Target Maintained With a $4.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2585211734","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585211734?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:29","pubTimestamp":1763724540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PMN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 21, 2025 06:29 ET (11:29 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PMN"],"gpt_icon":0},{"id":"2585117726","title":"PTS Announces Official Launch of PMN on Republic -- Japan's First Compliant STO Offered in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2585117726","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585117726?lang=en_us&edition=fundamental","pubTime":"2025-11-21 19:25","pubTimestamp":1763724300,"startTime":"0","endTime":"0","summary":"YOKOHAMA, Japan, Nov. 21, 2025 /PRNewswire/ -- Pivotal Trend Service Co., Ltd.  today announced the official launch of its flagship digital asset product, PMN , on Republic, marking a significant milestone for the global digital securities industry. PMN becomes the first Japan-originated Security TokenOffering  to be compliantly offered in the United States, and the first STO launched following Republic's recent acquisition of INX.Designed as a compliant, Bitcoin-linked financial product, PMN aims to transform institutional-grade Bitcoin mining exposure into an accessible, transparent, and user-centric investment opportunity. Built on long-term mining infrastructure and a regulated token framework, PMN provides investors with structured, real-economy Bitcoin production over a fixed 36-month term.PTS has already completed over USD 2 million in early PMN pre-sales from global institutional investors. This early traction validates PMN's yield model and underscores the growing demand for c","market":"us","thumbnail":"https://mma.prnewswire.com/media/2829575/Pivotal_Trend_Service_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2829575/Pivotal_Trend_Service_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/pts-announces-official-launch-of-pmn-on-republic--japans-first-compliant-sto-offered-in-the-united-states-302623106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7507","MBTmain","09439","03008","BK7142","BK4594","03042","BK4588","83042","BK4139","BTC.USD.CC","PMN","03439","BK4211","BK4601","BTC.USD.HKCC","UBCP","BK1611","STO.AU","09042","BK4585"],"gpt_icon":1},{"id":"2584947385","title":"ProMIS Neurosciences Inc. held special shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2584947385","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584947385?lang=en_us&edition=fundamental","pubTime":"2025-11-19 22:26","pubTimestamp":1763562406,"startTime":"0","endTime":"0","summary":"ProMIS Neurosciences Inc. held a special meeting of shareholders on November 17, 2025. At the meeting, shareholders approved a proposal authorizing a potential share consolidation at a ratio ranging from one-for-five up to one-for-twenty-five, with the final ratio and timing to be determined by the Board of Directors. Shareholders also approved a proposal allowing for the adjournment of the meeting if necessary to solicit additional proxies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProMIS Neurosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 19, 2025, and is so","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDLbRngXH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4139"],"gpt_icon":0},{"id":"2584581954","title":"Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY) and ProMIS Neurosciences (PMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584581954","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584581954?lang=en_us&edition=fundamental","pubTime":"2025-11-19 00:20","pubTimestamp":1763482811,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Butterfly Network (BFLY – Research Report) and ProMI...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-butterfly-network-bfly-and-promis-neurosciences-pmn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-butterfly-network-bfly-and-promis-neurosciences-pmn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","LU0128526141.USD","BK4581","LABU","LU0029874061.USD","BK4588","BK4137","BK4139","PMN","XBI","HCSG","BFLY","BK4585","XLV"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.promisneurosciences.com","stockEarnings":[{"period":"1week","weight":-0.0489},{"period":"1month","weight":-0.1765},{"period":"3month","weight":-0.2254},{"period":"6month","weight":-0.316},{"period":"1year","weight":-0.6213},{"period":"ytd","weight":-0.6392}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.298191},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.061971},{"month":3,"riseRate":0,"avgChangeRate":-0.061506},{"month":4,"riseRate":0.666667,"avgChangeRate":0.13153},{"month":5,"riseRate":0,"avgChangeRate":-0.176878},{"month":6,"riseRate":0,"avgChangeRate":-0.154013},{"month":7,"riseRate":0.333333,"avgChangeRate":0.096733},{"month":8,"riseRate":0,"avgChangeRate":-0.185569},{"month":9,"riseRate":0.5,"avgChangeRate":-0.048217},{"month":10,"riseRate":0.25,"avgChangeRate":-0.042317},{"month":11,"riseRate":0,"avgChangeRate":-0.242658},{"month":12,"riseRate":0.5,"avgChangeRate":0.005357}],"exchange":"NASDAQ","name":"ProMIS Neurosciences Inc","nameEN":"ProMIS Neurosciences Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ProMIS Neurosciences Inc(PMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ProMIS Neurosciences Inc,PMN,ProMIS Neurosciences Inc股票,ProMIS Neurosciences Inc股票老虎,ProMIS Neurosciences Inc股票老虎国际,ProMIS Neurosciences Inc行情,ProMIS Neurosciences Inc股票行情,ProMIS Neurosciences Inc股价,ProMIS Neurosciences Inc股市,ProMIS Neurosciences Inc股票价格,ProMIS Neurosciences Inc股票交易,ProMIS Neurosciences Inc股票购买,ProMIS Neurosciences Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ProMIS Neurosciences Inc(PMN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ProMIS Neurosciences Inc(PMN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction